# Antithrombotic Therapy Guide: Level of Intensity Based on Indication

Patient Name: _____ Date of Birth: Y _____ / M _____ / Day _____
Laboratory: _____ Phone #: _____ Fax #: _____

| Indication/Clinical Situation | Antithrombotic Therapy |
|---|---|
| **Atrial fibrillation** | Low dose (LD) warfarin (INR 2.0-3.0) |
| **Mechanical Valve:** | |
| Bi-leaflet/Med-Hall in Aortic Position* | Low dose (LD) Warfarin (INR 2.0-3.0)* |
| Other disc or Starr Edwards valves | Medium dose (MD) Warfarin (INR 2.5-3.5) |
| MVR or AVR + *Embolic risk factor | Medium dose (MD) Warfarin (INR 2.5-3.5) |
| Old prosthesis, thromboembolism, Atherosclerosis | High dose (HD) Warfarin (INR 3.0-4.5) or MD Warfarin |
| + | LD ASA or Dipyridamole |
| AC Rx problems-bleeding | Low dose (LD) Warfarin + Dipyridamole or |
| | Low dose (LD) Warfarin + LD ASA |
| Recurrent Embolism | Consider other causes |
| **Bioprosthetic valve:** | |
| Routine: In NSR/No risk factors* | LD Warfarin X 3 months (then ASA) |
| AF, LA thrombus, Thromboembolism | MD Warfarin X 3 months, then LD Warfarin |
| ***Embolic Risk Factors:** Atrial fibrillation, LV dysfunction, prior thromboembolism, hypercoagulable conditions | |

**Warfarin Dosing:** ❍ LD INR=2.0-3.0 (target 2.5) ❍ MD INR=2.5-3.5 ❍ HD=INR 3.0-4.5

| Date | INR | Warfarin Dose Adjustment | Called | Re-Check | Billed |
|---|---|---|---|---|---|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |


© Continuing Medical Implementation® Inc. June 2006